Trials that use: Covariate adjustment
119 results
- SHIFTComplete statistical analysis of SHIFT, a randomized phase 3 trial evaluating ivabradine versus placebo in patients with chronic heart failure, including Cox proportional-hazards methods, hazard ratios, confidence intervals, p-values, safety, and statistical…
- SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
- SOLOIST-WHFIndependent statistical analysis of SOLOIST-WHF (NCT03521934), evaluating sotagliflozin versus placebo in participants with type 2 diabetes and worsening heart failure. Includes trial design, registered endpoints, Cox, ANCOVA and MMRM methodology, reported results,…
- SONARIndependent statistical analysis of the phase 3 SONAR trial of atrasentan versus placebo in diabetic nephropathy, including the composite renal endpoint, hazard ratios, confidence intervals, p-values, trial design, and statistical methodology.
- SPRING-2Independent statistical analysis of the SPRING-2 phase 3 trial comparing dolutegravir 50 mg once daily with raltegravir 400 mg twice daily for HIV-1 infection, including its non-inferiority design, stratified Cochran-Mantel-Haenszel analysis, confidence…
- STELLARIndependent statistical analysis of the phase 3 STELLAR trial of sotatercept plus background PAH therapy versus placebo plus background PAH therapy in pulmonary arterial hypertension, including trial design, endpoints, nonparametric analyses, hazard…
- STEP 2Complete statistical analysis of STEP 2, the randomized phase 3 trial of semaglutide in people with type 2 diabetes and overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression,…
- STEP-HFpEFIndependent statistical analysis of the phase 3 STEP-HFpEF trial of semaglutide in people living with heart failure and obesity, including trial design, ANCOVA methodology, primary endpoints, confidence intervals, p-values, safety, and interpretation.
- STRIVEComplete statistical analysis of the STRIVE phase 3 trial of erenumab for migraine prevention, including randomized trial design, primary and secondary endpoint analyses, mixed-effects models, Cochran-Mantel-Haenszel testing, multiplicity, and safety.
- SURMOUNT-OSAIndependent statistical analysis of SURMOUNT-OSA, a randomized phase 3 trial of tirzepatide in participants with obstructive sleep apnea and obesity, including AHI results, ANCOVA, logistic regression, confidence intervals, and safety.
- SUSTAIN-3Independent statistical analysis of SUSTAIN-3, the randomized phase 3 trial comparing once-weekly semaglutide 1.0 mg with exenatide ER 2.0 mg in subjects with type 2 diabetes receiving 1–2 oral antidiabetic drugs.
- SWITCH 1Independent statistical analysis of SWITCH 1 (NCT02034513), a randomized double-blind phase 3 crossover trial comparing insulin degludec with insulin glargine in type 1 diabetes, including its non-inferiority framework, Poisson regression, MMRM, McNemar…
- SWITCH 2Independent statistical analysis of SWITCH 2, a randomized double-blind crossover phase 3 trial comparing insulin degludec with insulin glargine in subjects with type 2 diabetes, including hypoglycaemia, HbA1c, crossover design, non-inferiority, and…
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…
- TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.
- TRA 2P-TIMI 50Independent statistical analysis of TRA 2P-TIMI 50 (NCT00526474), including randomized trial design, time-to-event endpoints, Cox proportional-hazards methods, efficacy results, bleeding outcomes, post-hoc analyses, and statistical interpretation.
- TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.